June HCV Advocate Newsletter: Drug Development News

June 2013 HCV Advocate Newsletter

 

In This Issue:

Drug Development News
Alan Franciscus, Editor-in-Chief
April has been a month that has been jam-packed with news about drugs that are being developed to treat chronic hepatitis C.  This article will focus on various news items that were released in April from AbbVie, Gilead, Janssen and Jennerex.  For information about the latest data released from the European Association for the Study of the Liver (EASL) conference see Liz Highleyman’s comprehensive review in this newsletter.

EASL 2013: DAAs Look Good, but Challenges Remain—Part 1
Liz Highleyman
Interferon-free Genotype 2 vs. 3
Interferon-sparing regimes have received the most attention at recent conferences, and EASL 2013 was no exception. Some combinations under study also dispense with ribavirin, which can cause anemia and other side effects.

HEALTHWISE: Hepatitis C and Men
Lucinda K. Porter, RN
Men account for two-thirds of the chronic hepatitis C virus infections (HCV) in the U.S. Men are more than twice as likely to die from HCV as women are. Approximately 5.4% of U.S. Veterans, particularly from the Vietnam War era, have HCV—triple that of the general U.S. population. The majority of Veterans with HCV are men.

DISABILITY & BENEFITS: Affordable Care Act in 2014
Jacques Chambers, CLU
Since being enacted in March, 2010, the Affordable Care Act (sometimes called ObamaCare) has already initiated some changes in healthcare delivery, permitting children to stay on parents’ coverage until age 26, covering preventive care at 100%, and prohibiting lifetime limits on benefits, just to name a few.

All Newsletters http://www.hcvadvocate.org/news/newsletter_2013.asp